TriangleGINAKIT2 (NCT03294954)
GINAKIT2 trial for Neuroblastoma (NCT03294954). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Neuroblastoma is a cancer of young children. When high-risk disease comes back, few treatments hold it.
The idea: use a rarer kind of immune cell, one that naturally walks into these tumors, and arm it.
Nearly all neuroblastoma cells carry a molecule called GD2. Natural killer T cells, a small subset of white blood cells, home to neuroblastoma and kill the macrophages that help it grow. Here, a child's own NKT cells are expanded, given a receptor for GD2, and a gene for interleukin-15 to help them last, then infused after chemotherapy.
In the first twelve children, there were no dose-limiting toxicities, and three tumors shrank, one completely.
GINAKIT2, at Texas Children's, led by Gengwen Tian, continues escalating. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.